The company said the drug showed meaningful reductions in the levels of LDL-C, or low-density lipoprotein, which is commonly known as bad cholesterol. Read more: https://pharma.economictimes.indiatimes.com/news/research-and-development/mercks-enlicitide-decanoate-achieves-significant-milestones-in-cholesterol-reduction-trials/121728727